Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies

SIMPLE SUMMARY: Low-dose metronomic chemotherapy has anti-angiogenic activity and inhibits tumor growth. Therefore, we investigated the benefits of low-dose metronomic maintenance therapy (MT) in high-risk neuroblastoma (NB) patients who are unable to undergo autologous stem cell transplantation (AS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Sun, Xiaofei, Zhen, Zijun, Guo, Ying, Gao, Yuanhong, Wang, Juan, Zhang, Yu, Zhu, Jia, Lu, Suying, Sun, Feifei, Huang, Junting, Cai, Ruiqing, Zhang, Yizhuo, Liu, Juncheng, Xiao, Zizheng, Zeng, Sihui, Liu, Zhuowei
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8303783/
https://ncbi.nlm.nih.gov/pubmed/34298713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143494
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars